Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world

Starting soon

Conditions studied: Acute Lymphobkastic Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

In brief

The goal of this retrospective observational study is to learn about the efficacy of ponatinib in Philadelphia-positive ALL (Ph+ ALL) patients in a real-world setting. The main goal of the study is to assess the rate of complete molecular response (CMR) induced by ponatinib in patients treated under the regulations of Law 648/96, outside clinical trials. Patients who were treated with ponatinib as part of their regular medical care and completed the follow-up period will be included in the study.

Key facts

Study ID

NCT07356960

Run by

Gruppo Italiano Malattie EMatologiche dell'Adulto

People needed

103

Starts

2026-04-02

Expected to finish

2029-06-30

Last updated by the study team

2026-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is > 18 years old;
• Patient was treated in first-line with ponatinib monotherapy or in association with chemotherapy or immunotherapy;
• Patient received ponatinib under the regulations of Law 648/96;
• - Patient is alive and have at least 18 months of retrospective observation available from the start of ponatinib treatment, OR
• has died/lost to follow-up at any time after treatment initiation, regardless of the length of available follow-up;
• Signed informed consent, if applicable.

You may not qualify if…

• None

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.